226 related articles for article (PubMed ID: 29098843)
1. [Analysis on regional distribution characteristics and changing trend of Chinese patent medicine industry].
Wang H; Zhang XB; Zhao YP; Shi TT; Yang G
Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(14):2814-2819. PubMed ID: 29098843
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of patent data of Panax notoginseng and enlightenment of industrial development].
Li G; Chen J; Li ZK; Wu W; Yang HJ
Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(5):1011-1022. PubMed ID: 32237440
[TBL] [Abstract][Full Text] [Related]
3. Sales practices of patent medicine sellers in Nigeria.
Adikwu MU
Health Policy Plan; 1996 Jun; 11(2):202-5. PubMed ID: 10158461
[TBL] [Abstract][Full Text] [Related]
4. [Evidence mapping of clinical research on 28 Chinese patent medicines for tension-type headache].
Guan YY; Yu XY; Li CY; Shu JZ; Tao WQ; Mi XJ; Luo XQ; Lian ZY; Zhao YH; Tang J; Liao X
Zhongguo Zhong Yao Za Zhi; 2021 Dec; 46(24):6558-6567. PubMed ID: 34994149
[TBL] [Abstract][Full Text] [Related]
5. [Design and implementation of supply security monitoring and analysis system for Chinese patent medicines supply in national essential medicines].
Wang H; Zhang XB; Huang LQ; Guo LP; Wang L; Zhao YP; Yang G
Zhongguo Zhong Yao Za Zhi; 2017 Nov; 42(22):4310-4313. PubMed ID: 29318827
[TBL] [Abstract][Full Text] [Related]
6. [Registration and review of Chinese patent drugs in Kunming and the compilation and revision of the
Yang ZQ
Zhonghua Yi Shi Za Zhi; 2017 Jul; 47(4):213-221. PubMed ID: 28954363
[TBL] [Abstract][Full Text] [Related]
7. [Research on evaluation criteria over quality as core index of high grade Chinese patent medicine].
Liu Y; Yu HC; Zhang J; Chen C; Cheng JT; Song ZH; Liu A
Zhongguo Zhong Yao Za Zhi; 2018 Nov; 43(21):4356-4360. PubMed ID: 30583641
[TBL] [Abstract][Full Text] [Related]
8. [Exploration and practice of post-marketing survival benefit evaluation of Chinese patent medicine for cancer].
Xu BW; Wu JY; Li J; Zhang Y; Cao LC; Zhang XX; Gao RK
Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1980-1987. PubMed ID: 33982508
[TBL] [Abstract][Full Text] [Related]
9. [Development strategy of Paris based on combination of domestic patent and current resource application and development].
Zhao FY; Tao AE; Xia CL
Zhongguo Zhong Yao Za Zhi; 2018 Jan; 43(2):404-409. PubMed ID: 29552863
[TBL] [Abstract][Full Text] [Related]
10. [Chinese Sanqi industry status and development countermeasures].
Cui XM; Huang LQ; Guo LP; Liu DH
Zhongguo Zhong Yao Za Zhi; 2014 Feb; 39(4):553-7. PubMed ID: 25204122
[TBL] [Abstract][Full Text] [Related]
11. [Thoughts on foreign universal drug value evaluation tools for construction of Chinese patent medicine value evaluation tools].
Zhang Q; Wang ZF; Xie YM; Li LX
Zhongguo Zhong Yao Za Zhi; 2021 Apr; 46(8):1973-1979. PubMed ID: 33982507
[TBL] [Abstract][Full Text] [Related]
12. [Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world].
Yang W; Xie Y; Zhuang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2779-82. PubMed ID: 22292363
[TBL] [Abstract][Full Text] [Related]
13. [Technical specification for Instructions for Clinical Application of Chinese Patent Medicines in China Association of Chinese Medicine].
Zhang XM; Sa RN; Zhang B; Zhang D; Lyu JT; Duan XJ; Lin ZJ; Guo YB
Zhongguo Zhong Yao Za Zhi; 2021 Sep; 46(17):4563-4568. PubMed ID: 34581062
[TBL] [Abstract][Full Text] [Related]
14. [Research status of Bovis Calculus and relevant Chinese patent medicines based on bibliometric analysis].
Wang J; Lu YY; Xie MX; He K; Shang BY; Wang T; Wang HQ
Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(8):2092-2102. PubMed ID: 37282898
[TBL] [Abstract][Full Text] [Related]
15. [Key points of poverty alleviation of Chinese herbal medicine industry and classification of recommended Chinese herbal medicines].
Huang LQ; Su GQ; Zhang XB; Sun XM; Wu XJ; Guo LP; Li M; Wang H; Jing ZX
Zhongguo Zhong Yao Za Zhi; 2017 Nov; 42(22):4319-4328. PubMed ID: 29318829
[TBL] [Abstract][Full Text] [Related]
16. [Construction of model for multidimensional evaluation of value and risk of Chinese patent medicine].
Li G; Li ZK; Yang HJ; Zhan ZL; Li HM; Tang SH
Zhongguo Zhong Yao Za Zhi; 2021 Mar; 46(5):1284-1292. PubMed ID: 33787124
[TBL] [Abstract][Full Text] [Related]
17. [Exploration and research on comprehensive evaluation model of Chinese patent medicines supply in national essential drugs].
Wang H; Huang LQ; Zhang XB; Zhao YP; Yang G
Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2612-2618. PubMed ID: 28840707
[TBL] [Abstract][Full Text] [Related]
18. [Expert consensus on prescription comment of Chinese traditional patent medicine for promoting the rational use of drugs in Beijing].
Jin R; Zhao KJ; Guo GM; Zhang B; Wang YG; Xue CM; Yang YH; Wang LX; Li GH; Tang JF; Nie LX; Zhang XL; Zhao TT; Zhang Y; Yan C; Yuan SZ; Sun LL; Feng XZ; Yan D;
Zhongguo Zhong Yao Za Zhi; 2018 Mar; 43(5):1049-1053. PubMed ID: 29676107
[TBL] [Abstract][Full Text] [Related]
19. [Pre-searching during formulation of expert consensus on clinical application of Chinese patent medicines:Yanshen Jianwei Capsules as example].
Feng X; Duan XJ; Sun JW; Guo YB
Zhongguo Zhong Yao Za Zhi; 2021 Aug; 46(16):4287-4292. PubMed ID: 34467743
[TBL] [Abstract][Full Text] [Related]
20. [Report standards for clinical comprehensive evaluation of Chinese patent medicine].
Zhang Q; Wang ZF; Xie YM; Li YY; Wang LX; Liu H; Geng HJ; Cui X; Liu FM; Sun CQ; Wei RL; Zhang LD
Zhongguo Zhong Yao Za Zhi; 2021 Dec; 46(23):6062-6067. PubMed ID: 34951233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
